Reply to Letter to Editor: Is SARS-CoV-2 responsible for relapses of Parkinson’s disease?

Walaa A. Kamel1,2, Ismail Ibrahim Ismail1*, Mohamed Ibrahim1 and Jasem Y. Al-Hashel1,3

Keywords: COVID-19, SARS-CoV-2, Parkinson’s disease, Parkinsonism

To the Editor

We read with interest the comments made by Scorza and colleagues [1] on our article regarding worsening of parkinsonian symptoms in a patient with advanced Parkinson’s disease (PD) as the sole initial presentation of COVID-19 infection [2]. Herein, we would like to respond to some points that were raised as concerns and comments. In our case, we ruled out various possible causes for clinical deterioration, as previously mentioned in our case description, along with normal initial computed tomography (CT) of the brain on presentation. We agree that cerebrospinal fluid (CSF) examination would be helpful in such cases; however, the lack of fever, signs of meningeal irritation on presentation, in addition to the overall outcome, ruled out CNS infection.

As regards to not performing dopamine transporter (DAT) scan, our patient had a typical history of PD, with good response to dopaminergic therapy, and a dopamine transporter (DAT) scan is not mandatory for either diagnosis or follow-up. The authors postulated that confusion in our patient could be related to mismanagement of his medications; however, there was no history of any change in his usual doses, even when the family noticed the unusual worsening of his symptoms on his current regimen, which did not contain dopamine agonists. Moreover, no adjustment of his L-dopa dose was needed following admission, as the patient needed ventilatory support that required a small dose of propofol to relax his muscles.

The authors suggested that respiratory distress could be related to a central etiology, which is unlikely in our case, in the context of severe COVID-19 infection. Moreover, Guillain–Barre syndrome (GBS) was not considered, as deep tendon reflexes were present, with the absence of any obvious weakness, as we recently reported such a case [3]. Although we have no evidence that the virus had entered the brain, worsening of PD symptoms is a known complication of any systemic infection without direct invasion to CSF. That was partly explained by Brugger and colleagues [4], through different mechanisms, including enhanced neurodegeneration by peripheral inflammation, downregulation of dopaminergic receptors, altered transport of dopaminergic drugs through the blood–brain barrier, altered presynaptic reuptake of L-dopa and dopamine, respectively, and impaired packaging of neurotransmitters into vesicles, among other explanations. Central dopaminergic hypoactivity associated with PD has been related to an increased risk of inflammation. Furthermore, recently it was shown that dopamine inhibits TRAF6-mediated NF-κB activation and inflammation via the D5 dopamine receptor in macrophages, and mutations in the LRRK2 gene are also found in some bacterial infections and autoimmune disorders [5, 6]. Supporting our claim, a genome-wide association study [7] reported that LRRK2 mutations, as the most common genetic cause of both familial and sporadic PD, has a role in regulating inflammatory responses systemically and in the brain, and are associated with autoimmune diseases [8].

Since no other apparent explanation of PD deterioration was determined, in addition to the improvement of the condition after stabilizing COVID-19 infection, we could suggest a probable association between...
SARS-CoV-2 infection and worsening of PD symptoms in our case.

Abbreviations
PD: Parkinson’s disease; COVID-19: Coronavirus disease 2019; CT: Computed tomography; CSF: Cerebrospinal fluid; CNS: Central nervous system; DAT: Dopamine transporter; GBS: Guillain–Barre syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Acknowledgements
Not applicable.

Authors’ contributions
WAK, III: design, literature search, discussion, first draft, critical comments. MI, JYA: discussion, critical comments, final approval. All authors read and approved the final manuscript.

Authors’ information
WAK‑MD, neurology specialist. III‑MD, neurology specialist. MI‑MD, neurology specialist. JYA‑MD, professor of neurology.

Funding
Not applicable.

Availability of data and materials
The data sets supporting the conclusion of this article are included within the article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
Authors confirm that they have no competing interests.

Author details
1 Department of Neurology, Ibn Sina Hospital, Gamal Abdel Nasser Street, Sabah Medical Area, Safat, Kuwait. 2 Department of Neurology, Beni‑Suef University, Beni‑Suef, Egypt. 3 Department of Medicine, Faculty of Medicine, Health Sciences Centre, Kuwait University, Jabriya, Kuwait.

References
1. Scorza FA, Finsterer J, Fiorini AC. Is SARS‑CoV‑2 responsible for relapses of Parkinson’s disease? Egypt J Neurol Psychiatry Neurosurg. 2021;57:90. https://doi.org/10.1186/s41983-021-00344-x.
2. Kamel WA, Ismail II, Ibrahim M, Al‑Hashel JY. Unexplained worsening of parkinsonian symptoms in a patient with advanced Parkinson’s disease as the sole initial presentation of COVID‑19 infection: a case report. Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):60. https://doi.org/10.1186/s41983-021-00314-3.
3. Kamel WA, Ibrahim Ismail I, Al‑Hashel JY. Guillain‑Barre syndrome following COVID‑19 infection: first case report from Kuwait and review of the literature. Dubai Med J. 2021;4:107–11. https://doi.org/10.1159/000513382.
4. Brugger F, Erro R, Balint B, Kägi G, Barone P, Bhatia KP. Why is there motor deterioration in Parkinson’s disease during systemic infections—a hypothetical view? NPJ Parkinsons Dis. 2015;1:15014. https://doi.org/10.1038/npjparkd.2015.14.
5. Engler H, Doenlen R, Rietker C, Engler A, Niemi MB, Besedovsky HO, del Rey A, Pacheco‑Lopez G, Feldon J, Scheldowski M. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson’s disease. Brain Behav Immun. 2009;23:518–26. https://doi.org/10.1016/j.bbi.2009.01.018.
6. Wu Y, Hu Y, Wang B, Li S, Ma C, Liu X, Moynagh PN, Zhou J, Yang S. Dopamine Uses the DRD5‑ARRB2‑PP2A Signaling Axis to Block the TRAF6‑Mediated NF‑kappaB Pathway and Suppress Systemic Inflammation. Mol Cell. 2020;78:42‑56.e46. https://doi.org/10.1016/j.molcel.2020.01.022.
7. Witoelar A, Jansen IE, Wang Y, Desikan RS, Gibbs JR, Blauwendraat C, Thompson WK, Hernandez DG, Djurovic S, Schork AJ, Bettella F. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74(7):780–92.
8. Wallings RL, Herrick MK, Tansey MG. LRRK2 at the interface between peripheral and central immune function in Parkinson’s. Front Neurosci. 2020;21(14):443.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.